Summary
Eight patients, of whom four had acute myeloid leukemia (AML) and four had chronic myeloid leukemia (CML) blast crisis, were treated with a combination of cytosine arabinoside (ARA-C: 1,600 mg/m2 in three patients, 1,200 mg/m2 in five patients), tetrahydrouridine (THU: 2,800 mg/m2 in two patients, 2,646 mg/m2 in one patient, 2,100 mg/m2 in five patients), and carboplatin (900 mg/m2 in four patients, 720 mg/m2 in one patient, 450 mg/m2 in three patients). As a result of this treatment, five of the eight patients became aplastic. Two of the four patients with CML blast crisis reverted to the chronic phase and two of the four patients with acute nonlymphocytic leukemia (ANLL) attained a remission (one partial remission and one complete remission). The major toxicities included myelosuppression, unacceptable hepatotoxicity, and diarrhea. Pharmacokinetics studies revealed that the addition of carboplatin did not significantly change the disposition of ARA-C. ARA-C levels were not significantly changed in comparison with those obtained in a prior study of ARA-C with THU (ARA-C plasma levels at 3 h, 2630±1170 ng/ml).
Similar content being viewed by others
References
Canetta R, Goodlow J, Smaldone L, et al. (1990) Pharmacologic characteristics of carboplatin: clinical experience. In: Bunn PA, Canetta R, Ozols RF (eds) Carboplatin (JM-8): current perspectives and future directions. W. B. Saunders, Philadelphia, pp 19–38
Early A, Preisler H, Slocum H, et al. (1982) A pilot study of high dose ARA-C for acute leukemia and refractory lymphoma. Cancer Res 42: 1587–1594
Fram RJ, Robichaud N, Bishov SD, et al. (1987) Interactions ofcis-diamminedichloroplatinum(II) with 1-B-d-arabinofuranosylcytosine in LoVo colon carcinoma cells. Cancer Res 47: 3360–3365
George CB, Mansour RP, Redmond J, et al. (1984) Hepatic dysfunction and jaundice following high-dose cytosine arabinoside. Cancer 54: 2360–2362
Goodell B, Leventhal B, Henderson E (1971) Cytosine arabinoside in acute granulocytic leukemia. Clin Pharmacol Ther 12: 599–606
Greco WR, Park HS, Rustum YM (1990) Application of a new approach for the quantitation of drug synergism to the combination ofcis-diamminedichloroplatinum and 1-B-d-arabinofuranosylcytosine. Cancer Res 50: 5318–5327
Herzig RH, Wolff SN, Lazarus HM, et al. (1983) High-dose cytosine arabinoside therapy for refractory leukemia. Blood 62: 361–369
Kreis W, Chan K, Budman DR, et al. (1988) Effect of tetrahydrouridine on the clinical pharmacology of 1-B-d-arabinofurosylcytosine when both drugs are coinfused over three hours. Cancer Res 48: 1337–1342
Kreis W, Budman DR, Chan K, et al. (1991) Therapy of pretreated advanced leukemia with cytosine arabinoside plus tetrahydrouridine: a phase I and clinical pharmacology study. Leukemia 5: 991–998
Lazarus H, Herzig G, Herzig R, et al. (1981) Central nervous system toxicity of high dose ARA-C. Cancer 48: 2577–2582
Lopez JA, Agarwal RP (1984) Acute cerebellar toxicity after high dose cytarabine associated with CNS accumulation of its metabolite, uracil arabinoside. Cancer Treat Rep 68: 1309–1310
Meyers FJ, Welborn J, Lewis JP, et al. (1989) Infusion carboplatin treatment of relapsed and refractory acute leukemia: evidence of efficacy with minimal extramedullary toxicity at intermediate doses. J Clin Oncol 7: 173–178
Mulligan L, Mellet L (1970) Inhibition of arabinosylcytosine deamination by tetrahydrouridine in the monkey. Pharmacologist 12: 221
Nand S, Messmore H, Patel R, et al. (1986) Neurotoxicity associated with systemic high dose cytosine arabinoside. J Clin Oncol 2: 1092–1097
Shea TC, Flaherty M, Elias A, et al. (1989) A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. J Clin Oncol 7: 651–661
Weinstein HJ, Mayer RS, Rosenthal DS, et al. (1980) Treatment of acute myelogenous leukemia in children and adults. N Engl J Med 303: 473–478
Wong P, Currie V, Mackey R, et al. (1979) Phase I evaluation of tetrahydrouridine combined with cytosine arabinoside. Cancer Treat Rep 63: 1245–1249
Yates JW, Glidewell O, Wiernik P, et al. (1982) Cytosine arabinoside with daunorubicin or Adriamycin for treatment of acute myelocytic leukemia: a CALGB study. Blood 60: 454–462
Author information
Authors and Affiliations
Additional information
Supported by the Don Monti Memorial Research Foundation
Rights and permissions
About this article
Cite this article
Marsh, J.H., Kreis, W., Barile, B. et al. Therapy of refractory/relapsed acute myeloid leukemia and blast crisis of chronic myeloid leukemia with the combination of cytosine arabinoside, tetrahydrouridine, and carboplatin. Cancer Chemother. Pharmacol. 31, 481–484 (1993). https://doi.org/10.1007/BF00685039
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00685039